Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?

Eur J Cancer. 2018 Apr:93:144-146. doi: 10.1016/j.ejca.2017.12.013. Epub 2018 Feb 3.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antineoplastic Agents, Immunological / adverse effects
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / secondary
  • Humans
  • Lung Neoplasms / chemically induced*
  • Lung Neoplasms / surgery
  • Lymphatic Metastasis
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Multiple Pulmonary Nodules / chemically induced*
  • Multiple Pulmonary Nodules / surgery
  • Pneumonia / chemically induced*
  • Pneumonia / surgery
  • Prognosis
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / secondary

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • pembrolizumab